NOLAN: Naproxen or Loratadine and Neulasta

PHASE2CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

November 1, 2012

Primary Completion Date

March 18, 2015

Study Completion Date

March 18, 2015

Conditions
Bone Pain in Stage I - III Breast Cancer
Interventions
DRUG

Naproxen

DRUG

Loratadine

BIOLOGICAL

Pegfilgrastim

Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.

DRUG

Chemotherapy

The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.

Trial Locations (83)

13057

Research Site, East Syracuse

13790

Research Site, Johnson City

18015

Research Site, Bethlehem

19047

Research Site, Langhorne

20850

Research Site, Rockville

21133

Research Site, Randallstown

21157

Research Site, Westminster

21502

Research Site, Cumberland

23320

Research Site, Chesapeake

25701

Research Site, Huntington

28054

Research Site, Gastonia

28374

Research Site, Pinehurst

28602

Research Site, Hickory

29506

Research Site, Florence

30901

Research Site, Augusta

31792

Research Site, Thomasville

32114

Research Site, Daytona Beach

32117

Research Site, Daytona Beach

33308

Research Site, Fort Lauderdale

33324

Research Site, Plantation

33426

Research Site, Boynton Beach

33805

Research Site, Lakeland

34652

Research Site, New Port Richey

34994

Research Site, Stuart

35661

Research Site, Muscle Shoals

37421

Research Site, Chattanooga

37620

Research Site, Bristol

39202

Research Site, Jackson

40202

Research Site, Louisville

40353

Research Site, Mount Sterling

40503

Research Site, Lexington

42003

Research Site, Paducah

43701

Research Site, Zanesville

44646

Research Site, Massillon

46237

Research Site, Indianapolis

46601

Research Site, South Bend

49017

Research Site, Battle Creek

50702

Research Site, Waterloo

51101

Research Site, Sioux City

53226

Research Site, Wauwatosa

53405

Research Site, Racine

53548

Research Site, Janesville

53792

Research Site, Madison

54476

Research Site, Weston

55805

Research Site, Duluth

56303

Research Site, Saint Cloud

57201

Research Site, Watertown

59101

Research Site, Billings

60031

Research Site, Gurnee

60076

Research Site, Skokie

60126

Research Site, Elmhurst

61801

Research Site, Urbana

62864

Research Site, Mount Vernon

63136

Research Site, St Louis

64132

Research Site, Kansas City

64507

Research Site, Saint Joseph

65101

Research Site, Jefferson City

67502

Research Site, Hutchinson

68106

Research Site, Omaha

70072

Research Site, Marrero

70503

Research Site, Lafayette

71103

Research Site, Shreveport

71301

Research Site, Alexandria

75093

Research Site, Plano

78404

Research Site, Corpus Christi

78412

Research Site, Corpus Christi

80122

Research Site, Littleton

80210

Research Site, Denver

80401

Research Site, Golden

84403

Research Site, Ogden

90501

Research Site, Torrance

90603

Research Site, Whittier

92801

Research Site, Anaheim

92835

Research Site, Fullerton

93454

Research Site, Santa Maria

95403

Research Site, Santa Rosa

97701

Research Site, Bend

99208

Research Site, Spokane

06360

Research Site, Norwich

06902

Research Site, Stamford

01854

Research Site, Lowell

03060

Research Site, Nashua

07834

Research Site, Denville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01712009 - NOLAN: Naproxen or Loratadine and Neulasta | Biotech Hunter | Biotech Hunter